PF 5057459

Drug Profile

PF 5057459

Alternative Names: CovX 241; CVX-241; PF-05057459

Latest Information Update: 26 Jan 2012

Price : $50

At a glance

  • Originator CovX
  • Developer Pfizer
  • Class Antibodies; Antineoplastics; Peptides
  • Mechanism of Action Angiopoietin-2 inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 10 Nov 2011 Discontinued - Phase-I for Solid tumours in USA (IV)
  • 14 Sep 2011 Pfizer terminates phase I trial in advanced Solid tumours in USA (NCT01004822)
  • 01 Mar 2010 Phase-I clinical trials in Solid tumours in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top